Key antidepressant from AZ/Targacept fails trial

The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's ($AZN) struggling R&D operation another stinging setback and walloping Targacept ($TRGT) with a meltdown in its share value this morning. Report

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.